Blockade of the interactions between CD28/CTLA-4 and their ligands, CD80 (B7, B7.1)/CD86 (B70, B7.2), is an attractive means to induce antigen-specific peripheral tolerance in autoimmune disease and organ transplantation. In this study, we generated and characterized a monoclonal antibody (Clone 4E5) against human CD80. 4E5 could recognize both human and mouse CD80 and suppress mixed lymphocyte reaction in vitro. To investigate their potency for clinical use, we further administrated 4E5 to a mouse lupus-like disease model (C57BL/J6) induced by Pristane. 4E5 could inhibit the immune response and attenuate the severity of lupus-like disease. The data showed 4E5 function and suggested that blockade of CD80/CD28 co-stimulatory signal pathway with 4E5 is a promising strategy to decelerate the progression of lupus-like disease and other autoimmune diseases.
LaffertyKJCunninghamAJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci1975; 53:27–42.
2.
ApplemanLJBoussiotisVA. T cell anergy and costimulation. Immunol Rev2003; 192:161–80.
3.
Bour-JordanHSalomonBLThompsonHLSantosRAbbasAKBluestoneJ A. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol2007; 179:1004–12.
4.
YangYRattsRBHussainRZNorthropSCBenLHLovett-RackeARackeMK. CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE. Eur J Immunol2007; 37: 2032–42.
5.
PoussinMATüzünEGoluszkoEScottBGYangHFrancoJUChristadossP. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J Immunol2003; 170:4389–96.
6.
GarinEHDiazLNMuWWasserfallCArayaCSegalMJohnsonRJ. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol2009; 20:260–6.
7.
HaanstraKGEndellJEstévâoDKondovaIJonkerM. Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys. Clin Exp Immunol2009; 158:91–8.
8.
GrothSFScheideggerD. Production of monoclonal antibodies: strategy tactics. J Immunol Methods1980; 35:1–21.
9.
XieFWangQChenY. Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues. Tissue Antigens2006; 67:307–17.
10.
KurodaYAkaogiJNacionalesDCWasdoSCSzaboNJReevesWHSatohMD. Instinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci2004; 78: 222–28.
11.
FrisoniLMcPhieLKangSAMonestierMMadaioMSatohMCaricchioR. Lack of chromatin and nuclear fragmentation in vivo impairs the production of lupus anti-nuclear antibodies. J Immunol2007; 179:7959–66.
12.
ChanOTHannumLGHabermanAMMadaioMPShlomchikMJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med1999; 189:1639–48.
13.
ChanOTMadaioMPShlomchikM. B cells are required for lupus nephritis in the polygenic: Fas-intact MRL model of systemic autoimmunity. J Immunol1997; 163:3592–96.
14.
ChambersCAAllisonJP. Costimulatory regulation of T cell function. Curr Opin Cell Biol1999; 11:203–10.
15.
JudithLKatharinaGPPeterS. Receptor and ligands implicated in hunman T cell costimulatory process. Immunol Lett2010; 128:89–89.
16.
ShinTKennedyGGorskiK. Cooperative B7-1/2(CD80/CD86) and B7-DC costimulation of CD4+ T Cells independent of the PD-1 receptor. J Exp Med2003; 198:31–8.
17.
ButteMJPeña-CruzVKimMJFreemanGJSharpeAH. Interaction of human PD-L1 and B7-1. Molec Immunol2008; 45:3567–72.
18.
DavidsonADiamondBWofsyDDaikhD. Block and tackle: CTLA4Ig takes on lupus. Lupus2005; 14:197–203.
19.
Dall'EraMWofsyD. Biologic therapy for systemic lupus erythematosus. Discov Med2010; 9:20–3.
20.
PollardLC. Inhibiting costimulatory activation of T cells: a viable treatment option for rheumatoid arthritis?Drugs2007; 67:1–9.
21.
AsaiTChoiBKKwonPMKimWYKimJDVinayDSGebhardtBMKwonBS. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice. Immunology2007; 121:349–58.
22.
FordMLLarsenCP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev2009; 229:294–306.
23.
KrishnanSBChowdhuryTsokosGC. Autoimmunity in systemic lupus erythematosus: integrating genes and biology. Semin Immunol2006; 18:230–43.
24.
LiuMFLiJSWengTHLeiHY. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus. Scand J Immunol1999; 49:82–7.
25.
WongCKLitLCTarnLSLiEKLamCW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford)2005; 44:989–94.
26.
TakasakiYAbeKTokanoYHashimotoH. The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Intern Med1999; 38:175–77.
27.
AbeKTakasakiYUshiyamaCAsakawaJFukazawaTSekiMHirashimaMOgakiMHashimotoH. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. Clin Immunol1999; 19:58–66.
28.
DenfeldRWKindPSontheimerRDSchöpfESimonJC. In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Arthritis Rheum1997; 40:814–21.
29.
KinoshitaKTeschGSchwartingAMaronRSharpeAHKelleyVR. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol2000; 164:6046–56.
FreemanGJGrayGSGimmiCDLombardDBZhouLJWhiteMFingerothJDGribbenJGNadlerLM. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med1991; 174:625–31.
32.
SatohMReevesWH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med1994; 180:2341–6.
33.
SatohMKumarAKanwarYSReevesWH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci1995; 92:10934–38.
34.
NacionalesDCKellyKMLeePY. Type 1 interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl pentadecane (pristane). Am J Pathol2006; 168:1227–40.
35.
ArleneTTElenaP. B-cell-directed therapies in systemic lupus erythematosus. S Arthritis Rheum2008; 38:218–27.
36.
HayashiT. Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J Biomed Biotechnol2010; 2010:1–19.
37.
CaleroISanzI. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?Discov Med2010; 10:416–24.
38.
ZhangJLSunDJHouCM. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidneyTranspl Immunol2010; 24:17–25.
